Previous reports reveal that TAK1-TAB2/3-MAPK pathway is the essential hub in the initiation and progression of NAFLD, including lipid metabolism, inflammation, and liver injury (18, 19), thus we speculate that TRIM38 might participate in the regulation of NAFLD. The gene discussed is TAB2; the disease is metabolic dysfunction-associated steatotic liver disease.